| Mechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal. | Mechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal.
Tang H, Xiao Y, Qian L, Wang Z, Lu M, Yao N, Zhou T, Tian F, Cao L, Zheng P, Dong X., Free PMC Article | 04/16/2024 |
| Behcet syndrome: The disturbed balance between anti- (CLEC12A, CLC) and proinflammatory (IFI27) gene expressions. | Behçet syndrome: The disturbed balance between anti- (CLEC12A, CLC) and proinflammatory (IFI27) gene expressions.
Oğuz AK, Oygür ÇŞ, Taşır S, Özdağ H, Akar MN., Free PMC Article | 05/1/2023 |
| Identification of two early blood biomarkers ACHE and CLEC12A for improved risk stratification of critically ill COVID-19 patients. | Identification of two early blood biomarkers ACHE and CLEC12A for improved risk stratification of critically ill COVID-19 patients.
Kattner S, Müller J, Glanz K, Manoochehri M, Sylvester C, Vainshtein Y, Berger MM, Brenner T, Sohn K., Free PMC Article | 04/4/2023 |
| Mycobacterial mycolic acids trigger inhibitory receptor Clec12A to suppress host immune responses. | Mycobacterial mycolic acids trigger inhibitory receptor Clec12A to suppress host immune responses.
Nishimura N, Tomiyasu N, Torigoe S, Mizuno S, Fukano H, Ishikawa E, Katano H, Hoshino Y, Matsuo K, Takahashi M, Izumi Y, Bamba T, Akashi K, Yamasaki S. | 02/4/2023 |
| CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia. | CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
Li Q, Liang C, Xu X, Zhang C, Cao W, Wang M, Jiang Z, Xing H, Yu J. | 10/15/2022 |
| Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy. | Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A, Dharmani-Khan P, Luider J, Auer I, Shabani-Rad MT., Free PMC Article | 02/12/2022 |
| The Fusion of CLEC12A and MIR223HG Arises from a trans-Splicing Event in Normal and Transformed Human Cells. | The Fusion of CLEC12A and MIR223HG Arises from a trans-Splicing Event in Normal and Transformed Human Cells.
Dhungel BP, Monteuuis G, Giardina C, Tabar MS, Feng Y, Metierre C, Ho S, Nagarajah R, Fontaine ARM, Shah JS, Gokal D, Bailey CG, Schmitz U, Rasko JEJ., Free PMC Article | 01/22/2022 |
| Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. | Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T., Free PMC Article | 01/22/2022 |
| Regulation of the Expression, Oligomerisation and Signaling of the Inhibitory Receptor CLEC12A by Cysteine Residues in the Stalk Region. | Regulation of the Expression, Oligomerisation and Signaling of the Inhibitory Receptor CLEC12A by Cysteine Residues in the Stalk Region.
Vitry J, Paré G, Murru A, Charest-Morin X, Maaroufi H, McLeish KR, Naccache PH, Fernandes MJ., Free PMC Article | 10/30/2021 |
| The Inhibitory Receptor CLEC12A Regulates PI3K-Akt Signaling to Inhibit Neutrophil Activation and Cytokine Release. | The Inhibitory Receptor CLEC12A Regulates PI3K-Akt Signaling to Inhibit Neutrophil Activation and Cytokine Release.
Paré G, Vitry J, Merchant ML, Vaillancourt M, Murru A, Shen Y, Elowe S, Lahoud MH, Naccache PH, McLeish KR, Fernandes MJ., Free PMC Article | 10/2/2021 |
| CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. | CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T. | 07/24/2021 |
| C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study. | C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study.
Wang J, Wang W, Chen H, Li W, Huang T, Zhang W, Ling W, Lai P, Wang Y, Geng S, Li M, Du X, Weng J., Free PMC Article | 05/29/2021 |
| Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. | Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
Matsuo H, Wakita T, Hiramatsu H, Ohmori K, Kodama K, Nakatani K, Kamikubo Y, Iwamoto S, Kondo T, Takaori-Kondo A, Takita J, Tomizawa D, Taga T, Adachi S. | 05/1/2021 |
| our data suggest that an anti-CLL-1-antibody-drug conjugate (ADC) has the potential to become an effective and safer treatment for acute myeloid leukemia (AML) in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML. | An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B, Yu SF, Del Rosario G, Leong SR, Lee GY, Vij R, Chiu C, Liang WC, Wu Y, Chalouni C, Sadowsky J, Clark V, Hendricks A, Poon KA, Chu W, Pillow T, Schutten MM, Flygare J, Polson AG. | 04/25/2020 |
| Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. | Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L. | 01/4/2020 |
| these data can help determine which cells will be spared during CLEC12A-targeted therapy, and we propose CLEC12A to be included in future studies of myeloid cancer stem cell biology. | Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.
Bill M, B van Kooten Niekerk P, S Woll P, Laine Herborg L, Stidsholt Roug A, Hokland P, Nederby L., Free PMC Article | 11/2/2019 |
| The CLL-1 chimeric antigen receptor-T cells specifically lysed CLL-1(+) cell lines as well as primary acute myeloid leukemia patient samples in vitro. | CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, Wang W, Xu L, Liao S, Liu W, Wang Y, Liu N, Zhang J, Xia X, Kang T, Chen G, Cai X, Yang H, Zhang X, Lu Y, Zhou P., Free PMC Article | 10/26/2019 |
| Awareness of minor normal CLEC12A+ subpopulations is crucial when using CLEC12A as a minimal residual disease marker in myeloid malignancies. | The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia.
Toft-Petersen M, Stidsholt Roug A, Plesner T, Ebbesen L, Brown GD, Nederby L. | 05/11/2019 |
| Enumeration of circulating hMICL+ stem cells by flow cytometry can discriminate between myeloproliferative neoplasm phenotypes and holds potential for monitoring disease evolution. | Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Herborg LL, Nederby L, Hasselbalch HC, Aggerholm A, Roug AS. | 10/13/2018 |
| CLL-1 is a novel prognostic predictor that could be exploited to supplement the current acute myeloid leukemia prognostic risk stratification system. | Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34(+) Acute Myeloid Leukemia.
Wang YY, Chen WL, Weng XQ, Sheng Y, Wu J, Hao J, Liu ZY, Zhu YM, Chen B, Xiong SM, Chen Y, Chen QS, Sun HP, Li JM, Wang J., Free PMC Article | 06/2/2018 |
| BMI-1, TIM-3 and CLL-1 have roles in acute myeloid leukemia prognosis and therapy | Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH, Sudha T, Godugu K, Elbaz O, Abdelghaffar HA, Hassan EE, Mousa SA., Free PMC Article | 02/24/2018 |
| The CLEC12A is an effective new candidate with great potential for in vivo Ag delivery into mDCs and pDCs, thereby using the specialized functions and cross-talk capacity of these DC subsets to boost tumor-reactive T cell immunity in cancer patients. | CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.
Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, Joosten B, Cambi A, Heemskerk MH, Franssen GM, Boerman OC, Bakker LB, Jansen JH, Schaap N, Dolstra H, Hobo W. | 10/7/2017 |
| Due to the absence of CLEC12A on normal haematopoietic stem cells, CLEC12A stem cell immunophenotyping may contribute to diagnosing and monitoring MDS patients and could furthermore add knowledge about disease propagating cells in MDS. | Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.
Toft-Petersen M, Nederby L, Kjeldsen E, Kerndrup GB, Brown GD, Hokland P, Stidsholt Roug A., Free PMC Article | 05/20/2017 |
| We propose the hypothesis that decreased expression of CLEC12A is a common denominator in the hyperinflammatory responses observed in Behcet's syndrome and gout. | C-type lectin domain family 12, member A: A common denominator in Behçet's syndrome and acute gouty arthritis.
Oğuz AK, Yılmaz S, Akar N, Özdağ H, Gürler A, Ateş A, Oygür ÇŞ, Kılıçoğlu SS, Demirtaş S. | 04/30/2016 |
| Antibacterial autophagy is impaired in CLEC12A-deficient cells, and this effect is exacerbated in the presence of the ATG16L1( *)300A risk allele. | Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy.
Begun J, Lassen KG, Jijon HB, Baxt LA, Goel G, Heath RJ, Ng A, Tam JM, Kuo SY, Villablanca EJ, Fagbami L, Oosting M, Kumar V, Schenone M, Carr SA, Joosten LA, Vyas JM, Daly MJ, Netea MG, Brown GD, Wijmenga C, Xavier RJ., Free PMC Article | 03/26/2016 |